Loading organizations...
Loading organizations...
AnaBios: Preclinical CRO offering human-focused drug discovery services, ex vivo testing, and primary cells for pharmaceutical and biotech research.
Based in San Diego, California, AnaBios is a preclinical contract research organization that provides human-focused drug discovery services and ethically sourced tissue testing. The company supplies human primary cells and conducts advanced ex-vivo safety and efficacy assays to help researchers evaluate novel compounds for cardiac, neurological, pain, and respiratory diseases before initiating clinical trials. Operating with an estimated 50 to 150 employees, the firm generates revenue through direct product sales, specialized research partnerships, and an internal drug discovery platform utilizing in-licensed programs. AnaBios serves major global Fortune 500 pharmaceutical companies, biotechnology firms, and leading academic institutions, and it recently expanded its portfolio through the strategic acquisition of Cell Systems alongside a majority growth equity investment from Ampersand Capital Partners. The organization was originally founded in 2009 by co-founders Andre Ghetti and Jack A. Reynolds.
AnaBios has raised $15.0M across 2 funding rounds.
AnaBios has raised $15.0M in total across 2 funding rounds.
AnaBios has raised $15.0M in total across 2 funding rounds.
AnaBios's investors include Principia, Tech Coast Angels.
AnaBios has raised $15.0M across 2 funding rounds. Most recently, it raised $14.2M Other Equity / Series B in December 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 27, 2016 | $14.2M Other Equity / Series B | Principia | |
| Apr 4, 2011 | $800K Series A | Tech Coast Angels |